AZTherapies

About:

AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.

Website: http://www.aztherapies.com

Top Investors: Wexford Capital, THE CATALYTIC IMPACT FOUNDATION (CIF), DRADS Capital, Spinnaker Capital, Cosine

Description:

AZTherapies is an advanced clinical-stage biopharmaceutical company developing novel therapies that aim to fundamentally change neurodegenerative disease progression, extending normal cognition and function and improving quality of life in the aging population. Advancing a growing pipeline to treat patients with few therapeutic options, the Company’s lead candidate, ALZT-OP1, is built on a multi-modal approach that recognizes neuroinflammation as a root cause of serious neurodegeneration and seeks to stop or slow the progression of the disease. The Phase 3 COGNITE trial in early Alzheimer’s disease is fully enrolled and expected to complete in late 2020. Following the lead program, AZTherapies is advancing candidates for the treatment of post-ischemic stroke cognitive impairment, amyotrophic lateral sclerosis (ALS), and other indications. AZTherapies is a private company founded in 2011 and headquartered in Boston, Massachusetts.